Filter Results:
(401)
Show Results For
- All HBS Web (401)
- Faculty Publications (99)
Show Results For
- All HBS Web (401)
- Faculty Publications (99)
- 03 Apr 2009
- Working Paper Summaries
Applying the Care Delivery Value Chain: HIV/AIDS Care in Resource Poor Settings
- 03 Mar 2008
- First Look
First Look: March 4, 2008
the most important components of saving plans, do they even plan for retirement? This paper shows that financial illiteracy is widespread among the U.S. population and particularly acute among specific demographic groups, such as those... View Details
Keywords: Martha Lagace
- Program
Strategic Perspectives in Nonprofit Management
action and create a more responsive, successful, and sustainable nonprofit organization. Details Under take strategic analysis that positions your organization to thrive and grow Focus your mission and create service offerings that truly address the needs of your... View Details
- October 2009 (Revised August 2014)
- Case
Tengion: Bringing Regenerative Medicine to Life
By: Elie Ofek and Polly Ross Ribatt
Tengion is a young biotech company that is at the frontier of regenerative medicine—a nascent field that seeks to promote the creation of new cells and tissue to repair or replace tissue or organ function lost due to age, disease, damage, or congenital defects. In late... View Details
Keywords: Decision Choices and Conditions; Financial Crisis; Entrepreneurship; Health Care and Treatment; Technological Innovation; Product Launch; Product Development; Research and Development; Biotechnology Industry; United States
Ofek, Elie, and Polly Ross Ribatt. "Tengion: Bringing Regenerative Medicine to Life." Harvard Business School Case 510-031, October 2009. (Revised August 2014.)
- October 2010 (Revised November 2010)
- Background Note
Plavix: Drugs in the Age of Personalized Medicine
By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even... View Details
Keywords: Health Care and Treatment; Product Positioning; Business and Government Relations; Genetics; Competitive Strategy; Pharmaceutical Industry
Hamermesh, Richard G., Mara G. Aspinall, and Rachel Gordon. "Plavix: Drugs in the Age of Personalized Medicine." Harvard Business School Background Note 811-001, October 2010. (Revised November 2010.)
- 23 Dec 2014
- First Look
First Look: December 23
to the global population was a challenge. Health care costs accounted for 10% of world GDP by 2013. In the U.S., health care costs were expected to top $3.1 trillion in 2014.... View Details
Keywords: Carmen Nobel
- 30 May 2024
- Research & Ideas
Racial Bias Might Be Infecting Patient Portals. Can AI Help?
convenience and speed. The report’s conclusion invites further study. Explanations for the disparities that the authors document range from differences in the types of questions or requests made by patients in the messages, the syntax of the message and its level of... View Details
- 2010
- Chapter
From Visible Harm to Relative Risk: Centralization and Fragmentation of Pharmacovigilance
By: Arthur A. Daemmrich
Adverse drug reactions pose distinct but potentially catastrophic risks to patients, physicians, pharmaceutical firms, and regulators. Between the early 1960s and the present, national systems were built to collect, standardize, and respond to individual reports of... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Testing and Trials; Business and Government Relations; Risk and Uncertainty; Safety; Pharmaceutical Industry; United States
Daemmrich, Arthur A. "From Visible Harm to Relative Risk: Centralization and Fragmentation of Pharmacovigilance." Chap. 13 in The Fragmentation of U.S. Health Care: Causes and Solutions, edited by Einer Elhauge, 301–322. Oxford: Oxford University Press, 2010.
- 2018
- Working Paper
Zig-Zagging Your Way to Transformative Impact
By: V. Kasturi Rangan and Tricia Gregg
Achieving transformative impact has been much discussed by social entrepreneurs, funders, and consultants. These discussions have focused on issues of increasing impact and scale, but often with no clear distinction between the two terms. In order to provide clarity,... View Details
Keywords: Social Entrepreneurship; Performance Efficiency; Growth and Development; Outcome or Result; Strategy
Rangan, V. Kasturi, and Tricia Gregg. "Zig-Zagging Your Way to Transformative Impact." Harvard Business School Working Paper, No. 18-062, January 2018.
- January 2024 (Revised April 2024)
- Case
Target Malaria: Editing Mosquitoes through Gene Drives
By: Shikhar Ghosh and Shweta Bagai
Target Malaria, a non-profit research consortium, is exploring the application of CRISPR-Cas9 gene editing technology to combat malaria in Sub-Saharan Africa. Its approach uses gene drives, a revolutionary tool, to suppress the population of malaria-carrying... View Details
Keywords: Health Disorders; Technological Innovation; Nonprofit Organizations; Business Strategy; Genetics; Ethics; Governing Rules, Regulations, and Reforms; United States; United Kingdom; Burkina Faso; Africa
Ghosh, Shikhar, and Shweta Bagai. "Target Malaria: Editing Mosquitoes through Gene Drives." Harvard Business School Case 824-068, January 2024. (Revised April 2024.)
- 23 Jul 2020
- Blog Post
Why Plume? To Make a Difference in the World
professional background in health tech. He mentioned that the venture capital firm, General Catalyst, he worked for before school had just invested in a trans telehealth company. My jaw must have dropped on the sidewalk. I had thought it... View Details
- 26 Mar 2019
- First Look
New Research and Ideas, March 26, 2019
record health worker attendance and patient adherence to protocol, and they automatically prompt follow-up treatment. We combine data from surveys, independent field visits, and government registers to identify impacts on TB-control... View Details
Keywords: Dina Gerdeman
- Web
Great American Business Leaders of the 20th Century - Leadership
Stephen W. Sanger General Mills, 1995–Present David Sarnoff Radio Corporation of America, 1930–1966 Clarence Saunders Piggly Wiggly Stores, 1916–1924 George A. Schaefer Caterpillar Tractor Company, 1985–1990 Leonard D. Schaeffer Wellpoint View Details
- Web
Key Concepts - Institute For Strategy And Competitiveness
patients into paying customers, mergers, analytics, big data, personalized or precision medicine, and population health to name a few. None was successful in improving outcomes and controlling cost. On that... View Details
- 30 Mar 2010
- First Look
First Look: March 30
outcomes salient (Burns & Corpus, 2004), the bias did not emerge when the presentation did not draw attention to recent outcomes. Fixing Health Care on the Front Lines Author:Richard M.J. Bohmer Publication:Harvard Business Review 88,... View Details
Keywords: Sean Silverthorne
- Web
Technology & Operations Management - Faculty & Research
allocations of the current budget. Scaling to the population level, this equates to billions of dollars in funding—there are substantial gains from developing new ways of identifying and supporting productive scientists. 2025 Working... View Details
- 03 Oct 2023
- Research Event
Build the Life You Want: Arthur Brooks and Oprah Winfrey Share Happiness Tips
when they have very intense negative emotions there's something wrong with them. No, on the contrary, half of the population has unusually intense negative emotions. So one of the things that we do is we use a very famous psychological... View Details
Keywords: by HBS Staff
- 2018
- Chapter
The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century
By: Nicholas Bagley, Benjamin Berger, Amitabh Chandra, Craig Garthwaite and Ariel Dora Stern
On the 35th anniversary of the adoption of the Orphan Drug Act (ODA), we describe the enormous changes in the markets for therapies for rare diseases that have emerged over recent decades. The most prominent example is the fact that the profit-maximizing price of new... View Details
Keywords: Health Care and Treatment; Laws and Statutes; Research and Development; Investment; Markets; Monopoly
Bagley, Nicholas, Benjamin Berger, Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern. "The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century." Chap. 4 in Innovation Policy and the Economy, Volume 19, edited by Josh Lerner and Scott Stern, 97–137. University of Chicago Press, 2018.
- 11 Feb 2014
- First Look
First Look: February 11
Publications August 2013 American Journal of Managed Care The Impact of Electronic Health Record Use on Physician Productivity By: Adler-Milstein, Julia, and Robert S. Huckman Abstract—Objectives: To examine the impact of the degree of... View Details
Keywords: Sean Silverthorne
- 21 Dec 2010
- First Look
First Look: December 21
hospital, considers which organizational structure will help them adjust to the changing health sector environment. The move from global budget to activity-based funding has led his and many other public hospitals to suffer losses in... View Details